CSHL 2022 Mechanisms & Models of Cancer Conference

冷泉港实验室会议 癌症的机制和模型 2022年8月16日至20日 近年来产生了革命性的发现，揭示了背后的机制 从癌细胞和宿主的角度来看，癌症的发展和进展 回应。这些进展导致了靶向癌症治疗，延长了患者的生存时间， 以及新的基于免疫的疗法，在某些情况下，这些疗法已经治愈了以前的 难治性恶性肿瘤。令人震惊的技术发展使我们能够审问癌症 基因组和表观基因组具有前所未有的深度和复杂性，揭示了 肿瘤的异质性有助于癌症治疗，同时也使更准确的治疗监测成为可能。 功能基因组技术的进步使我们能够启动癌基因和肿瘤抑制基因 随心所欲地在体外和体内测定其功能。更强大的肿瘤模型，如有机化合物， 已经开发出来，揭示了对癌细胞生物学的新见解，同时使快速识别成为可能 以及新疗法的测试。随着结构生物学的进步，我们可以研究三维 致癌蛋白质和蛋白质复合体的结构，促进小分子抑制剂的开发 或拮抗抗体。强大的策略也让我们能够询问新陈代谢重新编程是如何 癌细胞，开启了利用新陈代谢的新治疗方法的可能性 漏洞。计算生物学的改进正在产生对生物网络和 肿瘤的进化。传播和使用这些技术、模式和基于机制的方法 在这个快速发展的领域，会议极大地促进了调查人员聚集在一起介绍和 公开讨论他们最新未发表的研究成果。我们还需要培养下一代 这一过程的一个重要部分是对年轻研究人员来说这是一个绝佳的机会， 例如研究生和博士后，展示他们的工作并与前辈一对一互动 调查人员。癌症在冷泉港实验室(CSHL)的机制和模型是 推动癌症研究下一次智力飞跃的主要工具之一，并推动 走进未来，造福癌症患者。个别会议的确切范围将是 根据公开提交的摘要作出决定。每届会议将由两名常设代表主持 该领域的科学家将根据提交的摘要确定每次会议的形式。这个 主席将在他们的会议中介绍和概述主题，并自己简要介绍最新情况 研究。将特别重视促进研究生的积极参与， 博士后研究员和新的研究人员，以及该领域的领先科学家。两位顶尖专家 癌症生物学的不同领域将在会议期间发表主旨演讲，还将有 成为该领域主要杰出人士的一次“遗产演讲”。预计这次会议将提供独特的 初级和高级调查员在不同领域交流数据和想法的机会 应用于癌症遗传学和肿瘤抑制基因的研究。鉴于过去的成功 在1996年至2020年期间在CSHL举行的关于这一主题的会议，我们预计将有大约400人参加 来自世界各地实验室的科学家。

COLD SPRING HARBOR LABORATORY CONFERENCE MECHANISMS AND MODELS OF CANCER August 16 - 20, 2022 Recent years have produced transformative discoveries that have revealed the mechanisms behind the development and progression of cancer, both from the perspective of the cancer cell and the host response. These advances have resulted in targeted cancer therapies that have extended patient survival, as well as new immune-based therapies that have, in select cases, resulted in cures of previously intractable malignancies. Stunning technological developments have enabled us to interrogate the cancer genome and epigenome with unprecedented depth and sophistication, uncovering the challenges that tumor heterogeneity imposes for cancer therapy, while also enabling more accurate therapeutic monitoring. Advances in functional genomic technologies allow us to turn oncogenes and tumor suppressor genes on an off at will in vitro and in vivo to determine their function. More robust tumor models, such as organoids, have been developed, revealing new insights into cancer cell biology, while enabling the rapid identification and testing of new therapeutics. With advances in structural biology, we can examine the three-dimensional structure of oncogenic proteins and protein complexes, facilitating development of small molecule inhibitors or antagonistic antibodies. Powerful strategies also allow us to interrogate how metabolic reprogramming in cancer cells, opening up the possibility of novel therapeutic approaches that exploit metabolic vulnerabilities. Improvements in computational biology are yielding new insights into biological networks and tumor evolution. Dissemination and use of these technologies, models and mechanism-based approaches in this fast-moving field is greatly facilitated by meetings that bring investigators together to present and openly discuss their latest unpublished research findings. We also need to train the next generation of leaders in the field, and an essential part of this process is this fantastic opportunity for young investigators, such as graduate students and postdocs, to present their work and interact one-on-one with senior investigators. The Mechanisms and Models of Cancer meeting at Cold Spring Harbor Laboratory (CSHL) is one of the premier vehicles for promoting the next intellectual leaps in cancer research and propelling the field into the future to the benefit of cancer patients. The precise scope of the individual sessions will be decided on the basis of the openly submitted abstracts. Each session will be chaired by two established scientists in the field, who will establish the format of each session based on submitted abstracts. The chairs will introduce and give an overview of the topics in their sessions and a brief update on their own research. Particular emphasis will be given to promoting the active participation of graduate students, postdoctoral fellows and new investigators, as well as of leading scientists in the field. Two leading experts in diverse areas of cancer biology will deliver keynote addresses during the conference, and there will also be a “legacy lecture” by a major luminary in the field. It is anticipated that the meeting will provide unique opportunities for the exchange of data and ideas by both junior and senior investigators in different areas of research as they apply to cancer genetics and tumor suppressor genes. Given the success of past meetings held at CSHL on this topic between 1996 and 2020, we anticipate the attendance of about 400 scientists from laboratories around the world.